Clinical Information

Cancer Hotspot Analysis requires a small amount of tumor tissue to deep sequence 207 target regions prone to mutation (hotspots) present on 50 genes known to affect tumor growth and response to treatment. Patients with refractory and/or advanced solid tumors and those for which there is no standard treatment may benefit from this test. Guidelines are being developed in collaboration with specialists for appropriate use in each type of cancer. This assay is performed on the Ion Torrent PGM platform and has been validated in the CLIA-certified Advanced Technology Laboratory (ATL) in both research and clinical settings.

The molecular profile of a tumor specimen may provide valuable information which has the potential to guide personalized cancer treatment and provide results necessary for enrollment into various clinical trials.  Next generation sequencing and targeted molecular therapy are core components of Personalized Cancer Care within the Spectrum Health Regional Cancer Center.